3 hours UroGen Pharma (NASDAQ:URGN) Receives “Outperform” Rating from OppenheimerMarketBeat
Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday.
XOppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday.
X